Company profile
Kymera Therapeutics, Inc.
NASDAQ:KYMRBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Tipasertideg | phase1 | — | 3 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07677059 | phase2 | recruiting | 2026-07-01 | 2028-12-01 | Kymera Therapeutics, Inc. | A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study |
| NCT04772885 | phase1 | completed | 2021-02-23 | 2022-10-20 | Kymera Therapeutics, Inc. | A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS) |
| NCT07323654 | phase2 | recruiting | 2026-01-28 | 2027-12-01 | Kymera Therapeutics, Inc. | A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma |
| NCT07217015 | phase2 | active_not_recruiting | 2025-11-24 | 2027-06-01 | Kymera Therapeutics, Inc. | A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis |
| NCT07412288 | phase1 | recruiting | 2026-02-23 | 2026-12-01 | Kymera Therapeutics, Inc. | First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants |
FDA applications (0)
No records yet.